Cancer

Titlesort descending Average Rating
Hypericine 83.33%
Hyperthermia adds to chemotherapy. 90.00%
Hyperthermia and Immunity. A Brief Overview 70.00%
Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer. 90.00%
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. 80.00%
Hypoxia in cancer: significance and impact on clinical outcome. 70.00%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp 50.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... 40.00%
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, 50.00%
Immunomodulatory effects of opioids. 90.00%
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. 60.00%
Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized ........ 90.00%
Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled m 80.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... 75.00%
Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort s
Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus. 100.00%
Improvement of the recurrence-free interval using biological adjuvant therapy in uveal melanoma. 100.00%
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. 90.00%
In vitro induction of apoptotic cell death in chronic lymphocytic leukemia by two natural products: preliminary study 70.00%
In vitro screening for the tumoricidal properties of international medicinal herbs 80.00%
In-vitro toxicity of Ukrain against human Ewing tumor cell lines. 90.00%
Increased risk of cancer subsequent to severe depression--a nationwide population-based study. 70.00%
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to... 80.00%
Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort 80.00%
Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain.
Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain 80.00%
Induction of apoptosis in cultured Chinese hamster ovary cells by Ukrain and its synergistic action with etoposide. 80.00%
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. 50.00%
Inhibition of angiogenesis by non-toxic doses of temozolomide. 50.00%
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 50.00%
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 50.00%
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. 100.00%
Inhibition of liver mitochondrial monoamine oxidase activity by alkaloids isolated from Chelidonium and Macleaya and by their de 80.00%
Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. 50.00%
Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angio.. 60.00%
Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. 70.00%
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of m 30.00%
Interaction between Ukrain and Naltrexone in the writhing syndrome test in mice 80.00%
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare 60.00%
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen 80.00%
Is it time to test metformin in breast cancer clinical trials? 90.00%
IS THERE A COVID VACCINE / CANCER CONNECTION? 100.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". 60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. 70.00%
IV Artesunate
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. 40.00%
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 50.00%
Local ultrasound hyperthermia as a component of radiotherapy for osteogenic sarcoma of tubular bones in children and adolescents 70.00%
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother 50.00%
Long term outcomes following surgical resection of myxopapillary ependymomas. 40.00%
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 50.00%
Low dose "Metronomic" Chemotherapy 89.00%
Low Dose naltrexone 100.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. 70.00%
Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast ca 80.00%
Low-dose naltrexone for disease prevention and quality of life. 95.00%
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid 55.00%
Medical Cannabis Compounds 70.00%
Melatonin 45.00%
Melatonin as biological response modifier in cancer patients. 80.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
Metabolic modulation of glioblastoma with dichloroacetate. 90.00%
Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy 80.00%
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. 80.00%
Metformin in the treatment of Cancer 77.00%
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. 80.00%
Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. 80.00%
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission 80.00%
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 90.00%
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. 60.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high... 80.00%
Metronomic chemotherapy: changing the paradigm that more is better. 90.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti 90.00%
Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer 80.00%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. 70.00%
Mistletoe as a treatment for cancer. Has no proved benefit, and can cause harm 20.00%
Mistletoe in conventional oncological practice: exemplary cases. 40.00%
Mistletoe Therapy in Cancer 83.33%
Mistletoe therapy in oncology 90.00%
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.
Modification of antinociceptive action of morphine by Ukrain in rodents 50.00%
Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. 80.00%
Morphometric and kinetic analysis of the growth of experimental sarcoma-45 in the presence of Ukrain 50.00%
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. 90.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. 100.00%
Mycoplasma infections and different human carcinomas. 90.00%
Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. 90.00%
N-Acetylcysteine: Multiple Clinical Applications 60.00%
National Cancer Institute, National Institute of Health: Developmental Therapeutics Program. NSC 631570: results of the Human Ce 80.00%
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. 60.00%
New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder 60.00%
New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival? 70.00%
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. 70.00%

Pages